RE:RE:RE:RE:Dumping was expected..Good summary capebretongirl.
I like Oncore ...
PressRelease June 10, 2019...
SZLS said "The agreement with Oncore pharma aims to deploy a total of 1,750,000 tests over the next 5 years".
PressRelease Oct 10, 2019..
Benelux population 30 million.
Oncore Pharma signed a multi-years agreement that has a value to SZLS of US$40 million.
Now Oncore is going after Germany...Population 84 million. In Germany almost 86% of the population is covered by Public Health Insurance (nice market).
Oncore Pharma seem to be very serious about reaching the 1,750,000 tests goal.
capebretongirl wrote:
My understanding is that Lind wanted to liquidate their many shares for cash and started a systematic dumping process which gave them a modest profit based on volume - frustrating for we investors but a legal reality. There is no indication that Lind willl be involved in the future - lessons learned by SZLS corporate. Companies like SZLS will always need cash and when the issuance of shares is involved, the risk of this sort of thing will always be present.
I think most investors involved with this stock are here because of the proven and patented science behind it. We need only look at the info and statistics provided by Tripp in his most recent presentation - it all makes too much sense and we are left scratching our heads as to why the sp is what it is. I believe this is simply because of the lack of advertising and public awareness of this science as Twitter, Facebook Linkedin etc. can only promote so much - unfortunately a media awareness program such as EXAS for example has, would cost millions that SZLS simply doesn`t have. We are all hoping that the upcoming analyst research report, Health Insurer success (if its there), Employers, Telehealth, Aristotle, Oncore etc. etc. will increase this awareness to the point where physicans buy in and promote this thing. As Nail and others have pointed out, Q4 should finally show some traction, but Q1-2 will be more interesting - its a slow moving train with the amount of dillution and debt that we have, but ultimately we are all hoping for the science to prove itself and that the blood testing route becomes an accepted alternative across the board.
When a stock as promising as this is sitting at .04 cents, I think optimism is warranted. One point I took from last week`s presentation was the mention of Germany for example on the Oncore front - if the Benelux deal with Body Check NL works out ($40 mil), that alone should be a revenue generator and the eventual add on of a country like Germany would be a huge catalyst. We now also have a Covid environment where telehealth is being promoted and the trickle down effect will not hurt SZLS as clients become more familiar with this process as an alternative.
Like everyone else, I look forward to next week`s Q4 results - they won`t be earth shattering but hopefully just good enough to show that revenue is starting to trickle in - all of which would point to much larger revenues and traction as we move on to upcoming quarters (read: Benelux kick n etc.). There is so much going on right now that we should be optimistic that traction is occuring - as you pointed out - Tripp is advertising this for success, however we all know promises have been made in the past - the largest of which was the $30 million to be realized last year.
Anyway, fingers crossed for next week!